HRP20020330A2 - Novel oligosaccharides, preparation method and pharmaceutical compositions containing same - Google Patents

Novel oligosaccharides, preparation method and pharmaceutical compositions containing same

Info

Publication number
HRP20020330A2
HRP20020330A2 HR20020330A HRP20020330A HRP20020330A2 HR P20020330 A2 HRP20020330 A2 HR P20020330A2 HR 20020330 A HR20020330 A HR 20020330A HR P20020330 A HRP20020330 A HR P20020330A HR P20020330 A2 HRP20020330 A2 HR P20020330A2
Authority
HR
Croatia
Prior art keywords
pharmaceutical compositions
compositions containing
preparation
containing same
novel oligosaccharides
Prior art date
Application number
HR20020330A
Inventor
Pierre Mourier
Christian Viskov
Jean-Marie Stutzmann
Florence Wahl
Elisabeth Perrin
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of HRP20020330A2 publication Critical patent/HRP20020330A2/en
Publication of HRP20020330B1 publication Critical patent/HRP20020330B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

The invention concerns oligosaccharides of formula (I), their mixtures, their diastereomers, methods for preparing them and pharmaceutical compositions containing them.
HR20020330A 1999-10-22 2002-04-15 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same HRP20020330A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9913182A FR2800074B1 (en) 1999-10-22 1999-10-22 NOVEL OLIGOSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PCT/FR2000/002897 WO2001029055A2 (en) 1999-10-22 2000-10-18 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same

Publications (2)

Publication Number Publication Date
HRP20020330A2 true HRP20020330A2 (en) 2004-04-30
HRP20020330B1 HRP20020330B1 (en) 2013-01-31

Family

ID=9551218

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020330A HRP20020330A2 (en) 1999-10-22 2002-04-15 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same

Country Status (31)

Country Link
EP (1) EP1226148B1 (en)
JP (1) JP4733329B2 (en)
KR (2) KR100778166B1 (en)
CN (1) CN1241932C (en)
AT (1) ATE534656T1 (en)
AU (1) AU781414B2 (en)
BR (1) BR0014939A (en)
CA (1) CA2388369C (en)
CY (1) CY1112274T1 (en)
CZ (1) CZ303255B6 (en)
DK (1) DK1226148T3 (en)
EA (1) EA004046B1 (en)
EE (1) EE05091B1 (en)
ES (1) ES2376409T3 (en)
FR (1) FR2800074B1 (en)
HK (1) HK1050535A1 (en)
HR (1) HRP20020330A2 (en)
HU (1) HU229385B1 (en)
IL (2) IL149154A0 (en)
ME (1) MEP9309A (en)
MX (1) MXPA02003945A (en)
NO (1) NO323409B1 (en)
NZ (1) NZ518539A (en)
PL (1) PL204623B1 (en)
PT (1) PT1226148E (en)
RS (1) RS50829B (en)
SK (1) SK287459B6 (en)
TR (1) TR200201102T2 (en)
UA (1) UA72545C2 (en)
WO (1) WO2001029055A2 (en)
ZA (1) ZA200203102B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4676048B2 (en) * 2000-07-10 2011-04-27 生化学工業株式会社 Demyelinating disease treatment
MXPA03004965A (en) * 2000-12-16 2003-09-25 Aventis Pharma Gmbh Use of low molecular heparin for treating osteoarthritis.
DE10121003A1 (en) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilic acid amides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
EP2284535A1 (en) 2002-03-11 2011-02-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparins
FR2844808B1 (en) * 2002-09-23 2005-02-25 Aventis Pharma Sa METHOD OF DETERMINING SPECIFIC GROUPS CONSISTING OF HEPARINS OR HEPARINS OF LOW MOLECULAR WEIGHT
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
US7511026B2 (en) * 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
FR2857971B1 (en) * 2003-07-24 2005-08-26 Aventis Pharma Sa MIXTURES OF HEPARIN DERIVED OLIGOSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US7956046B2 (en) * 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
EP1580197A1 (en) * 2004-03-24 2005-09-28 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular wieght heparins using HPLC
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
DE102005017799A1 (en) * 2005-04-18 2006-10-19 Abbott Gmbh & Co. Kg Use of heparin- or heparin derivative to treat illness associated with neurite plasticity or -growth defects, modulates interaction between Nogo receptor and ligands
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2256138A1 (en) 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated 1,6-anhhydro decasaccharide and its use as antithrombotic agent
FR2949115B1 (en) * 2009-08-14 2012-11-02 Sanofi Aventis FGF RECEPTOR ACTIVATOR N-SULFATE OLIGOSACCHARIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2949114B1 (en) * 2009-08-14 2011-08-26 Sanofi Aventis FGF RECEPTOR ACTIVATORY N-ACYLATED OCTASACCHARIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011090948A1 (en) 2010-01-19 2011-07-28 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN102864191A (en) * 2011-12-16 2013-01-09 深圳市海普瑞药业股份有限公司 Heparin disaccharide mixture and preparation method and application thereof
CN104910217B (en) * 2015-06-19 2018-04-17 天津红日药业股份有限公司 Reference compound for Fondaparinux sodium quality control
CZ308106B6 (en) * 2016-06-27 2020-01-08 Contipro A.S. Unsaturated derivatives of polysaccharides, preparing and using them
CN110092848A (en) * 2019-05-14 2019-08-06 山东辰龙药业有限公司 A kind of preparation method of Bemiparin sodium

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519987A1 (en) * 1982-01-15 1983-07-22 Choay Sa Uronic acid derivs. - useful as glycoside intermediates or hapten(s)
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
FR2764511B1 (en) * 1997-06-13 2000-09-08 Sanofi Sa COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF ARTERIAL THROMBOSIS AND USE OF A FACTOR XA INHIBITOR ALONE AND / OR IN COMBINATION WITH A PLAQUET ANTIAGGREGANT
JP4166851B2 (en) * 1997-09-29 2008-10-15 生化学工業株式会社 Novel inhibitor of ischemia / reperfusion injury

Also Published As

Publication number Publication date
FR2800074B1 (en) 2001-12-21
EA004046B1 (en) 2003-12-25
AU781414B2 (en) 2005-05-19
CN1379781A (en) 2002-11-13
SK287459B6 (en) 2010-10-07
EP1226148B1 (en) 2011-11-23
UA72545C2 (en) 2005-03-15
CZ20021385A3 (en) 2002-07-17
NO20021859L (en) 2002-06-13
KR20020063881A (en) 2002-08-05
EA200200479A1 (en) 2002-10-31
HU229385B1 (en) 2013-11-28
MEP9309A (en) 2011-12-20
PT1226148E (en) 2012-01-24
KR100872215B1 (en) 2008-12-05
NO20021859D0 (en) 2002-04-19
FR2800074A1 (en) 2001-04-27
HUP0203821A2 (en) 2003-04-28
CY1112274T1 (en) 2015-12-09
YU29802A (en) 2006-01-16
CA2388369C (en) 2011-02-01
KR100778166B1 (en) 2007-11-27
PL363052A1 (en) 2004-11-15
EE05091B1 (en) 2008-10-15
JP4733329B2 (en) 2011-07-27
HRP20020330B1 (en) 2013-01-31
CZ303255B6 (en) 2012-06-27
NZ518539A (en) 2004-10-29
NO323409B1 (en) 2007-04-30
EE200200208A (en) 2003-06-16
ZA200203102B (en) 2003-09-23
HK1050535A1 (en) 2003-06-27
SK5272002A3 (en) 2002-08-06
KR20070087263A (en) 2007-08-27
CN1241932C (en) 2006-02-15
WO2001029055A2 (en) 2001-04-26
CA2388369A1 (en) 2001-04-26
ES2376409T3 (en) 2012-03-13
BR0014939A (en) 2002-06-18
DK1226148T3 (en) 2012-03-19
JP2003512385A (en) 2003-04-02
MXPA02003945A (en) 2002-10-23
IL149154A0 (en) 2002-11-10
TR200201102T2 (en) 2002-12-23
HUP0203821A3 (en) 2003-10-28
RS50829B (en) 2010-08-31
WO2001029055A3 (en) 2002-02-14
EP1226148A2 (en) 2002-07-31
IL149154A (en) 2008-04-13
ATE534656T1 (en) 2011-12-15
AU7930200A (en) 2001-04-30
PL204623B1 (en) 2010-01-29

Similar Documents

Publication Publication Date Title
HK1050535A1 (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing same
AU2002239344A1 (en) Pyrazolopyridines
PL366198A1 (en) Novel compounds
HK1048990A1 (en) Novel compounds.
IL127581A0 (en) Crystal form i of clarithromycin
DE60116761D1 (en) Adamantanderivate
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
AP2002002458A0 (en) Compounds for the treatment of ischemia.
SE9901875D0 (en) Novel compounds
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
DE60112330D1 (en) Pyrazolopyridinderivate
HK1030218A1 (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same.
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
MXPA03001536A (en) Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same.
NZ515108A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
YU10599A (en) Amorphous benzothiophenes, procedure for the preparatio thereof and their pharmaceutical formulation
YU72802A (en) Pharmaceutical compositions containing oligosaccharides and preparation thereof
DE60201074D1 (en) Pyrazolopyridinderivate
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
SE9904128D0 (en) Novel compounds
EP1132383A4 (en) Novel agarofuan derivatives, their preparation, pharmaceutical composition containing them and their use as medicine
MXPA03010259A (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof.
CA2420056A1 (en) 1-amino-alkylcyclohexanes as trypanocidal agents
PL332480A1 (en) Novel heteroaruylooxyethylamines, method of obtaining them, their application as drugs as well as pharmaceutic compositions containing them

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130910

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20141018